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Microbiota modulation counteracts 
Alzheimer’s disease progression 
influencing neuronal proteolysis 
and gut hormones plasma levels
Laura Bonfili  1, Valentina Cecarini1, Sara Berardi1, Silvia Scarpona1, Jan S. Suchodolski2, 
Cinzia Nasuti3, Dennis Fiorini4, Maria Chiara Boarelli4, Giacomo Rossi1 & Anna Maria Eleuteri1
Gut microbiota has a proven role in regulating multiple neuro-chemical pathways through the highly 
interconnected gut-brain axis. Oral bacteriotherapy thus has potential in the treatment of central 
nervous system-related pathologies, such as Alzheimer’s disease (AD). Current AD treatments aim to 
prevent onset, delay progression and ameliorate symptoms. In this work, 3xTg-AD mice in the early 
stage of AD were treated with SLAB51 probiotic formulation, thereby affecting the composition of gut 
microbiota and its metabolites. This influenced plasma concentration of inflammatory cytokines and 
key metabolic hormones considered therapeutic targets in neurodegeneration. Treated mice showed 
partial restoration of two impaired neuronal proteolytic pathways (the ubiquitin proteasome system 
and autophagy). Their cognitive decline was decreased compared with controls, due to a reduction in 
brain damage and reduced accumulation of amyloid beta aggregates. Collectively, our results clearly 
prove that modulation of the microbiota induces positive effects on neuronal pathways that are able to 
slow down the progression of Alzheimer’s disease.
Alzheimer’s disease (AD) is a common, progressive, and irreversible neurodegeneration with a gradual loss of 
memory, judgment, and ability to function. Treating and managing AD patients is a severe burden, and there is an 
urgent need to discover and validate new therapeutic agents. Most cases of early-onset AD derive from a combi-
nation of genetic mutations in genes encoding amyloid precursor protein (APP) and presenilins 1 and 2 (PSEN1 
and PSEN2). APP cleavage by β and γ secretase complexes leads to the formation of amyloid-β (Aβ) peptides that 
can aggregate and form amyloid plaques, mainly composed of the 42 amino acid peptide (Aβ1–42), which is less 
abundant but more prone to aggregation than the Aβ1–40 peptide. Amyloid deposits and neurofibrillary tangles, 
comprising hyper phosphorylated tau protein, are the most important pathologic hallmarks of AD. Aβ deposition 
and clearance are finely regulated by the ubiquitin–proteasome system (UPS) and autophagy, which are tightly 
interrelated1–4. Impairment of proteolysis, which is characteristic of AD neurons, favors the accumulation of det-
rimental Aβ oligomeric structures that further contribute to proteasome and autophagy alterations.
Recently, several authors have described a role for gut peptide hormones in AD. These hormones are respon-
sible for energy homeostasis and food intake regulation and show effects on the central nervous system (CNS), 
modulating nervous functions like learning and memory5–7. Ghrelin is involved in glucose and lipid metabolisms, 
but also in higher brain functions such as learning and memory; it influences mitochondrial respiration and 
exerts neuroprotective effects, takes part in the aetiopathogenesis of neurodegenerative disorders, representing 
a link between metabolism and neurodegeneration8. Ghrelin and leptin act as neurotrophic factors protecting 
cells against toxicity induced by Aβ oligomers5, 9. Plasma leptin concentration is negatively correlated to Aβ levels 
due to its direct regulatory effect on γ-secretase10. In addition, animal models of AD treated with leptin showed a 
reduction in Aβ and phosphorylated tau levels11, 12. The age-related decline in plasma ghrelin concentration and 
1School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032, Camerino, 
(MC), Italy. 2Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary 
Medicine and Biomedical Sciences, Texas A&M University, College Station, USA. 3School of Pharmacy, Pharmacology 
Unit, University of Camerino, via Madonna delle Carceri, 62032, Camerino, (MC), Italy. 4Division of Chemistry, School 
of Science and Technology, University of Camerino, I-62032, Camerino, MC, Italy. Correspondence and requests for 
materials should be addressed to L.B. (email: laura.bonfili@unicam.it)
Received: 13 December 2016
Accepted: 12 April 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 2426  | DOI:10.1038/s41598-017-02587-2
the impairment of the ghrelin signaling observed in AD patients is closely related to the compromised memory 
and learning processes13. The glucagon-like peptide 1 (GLP-1) protects cultured neurons form oxidative damage 
and formation of Aβ plaques, and controls synaptic plasticity in mice14, 15. The use of glucose-dependent insu-
linotropic polypeptide (GIP) analogs as neuroprotective agents is an emerging and promising strategy in the 
treatment of AD16, 17.
Currently, no definitive treatment exists for AD, and most approaches aim to preserve cognition and memory 
and to delay the loss of function. Recent studies have highlighted a role for the human microbiome in regulating 
multiple neuro-chemical pathways through the highly interconnected host-microbiome system, the so-called 
gut-brain axis18–20. Oral bacteriotherapy is becoming an accepted practice for the prevention and treatment 
of allergies21, gastrointestinal infections22, inflammatory conditions23, 24 and cancer25. Beneficial effects of lac-
tic acid bacteria and bifidobacteria in CNS-related diseases such as multiple sclerosis, cognitive deficits, and 
stress-derived pathologies, have been recently documented26–31. Probiotic supplementation reverses cognitive 
impairment and ameliorates the spatial memory in diabetic rats32. It has recently been shown that the probiotic 
mixture VSL#3 modulates the expression of a number of genes in the brain cortex of aged rats, with positive con-
sequences on inflammatory and neuronal processes33. Moreover, bacterial byproducts such as short chain fatty 
acids (SCFAs) exert a number of neuromodulator effects and directly act on gastrointestinal cells stimulating the 
synthesis of hormones such as leptin and GLP-134, 35.
In the present study, a novel formulation of lactic acid bacteria and bifidobacteria (SLAB51) was administered 
to a triple-transgenic mouse model of Alzheimer’s disease, B6; 129-Psen1tm1Mpm Tg (APPSwe, tauP301L)1Lfa/J 
(named 3xTg-AD), in order to investigate the potential beneficial effects on memory deficits, amyloid plaque dep-
osition, and neuronal proteolysis impairment. To gain insight into the effects of microbiota on AD progression 
the modulation of the gut-brain axis upon administration of the probiotic mix was also investigated.
Methods
Experimental design. 8-week-old male 3xTg-ADmice (n = 64) were organized in two groups: a treated 
group (administered for 4 months with SLAB51 in water) and a control group (administered with water). 
Simultaneously, 64 coetaneous wild type (wt) mice were divided into wt control and wt treated groups. At 8, 12, 
18 and 24 weeks of age, 15 animals per group were given the open field (OF) and novel object recognition (NOR) 
tests. Elevated plus maze and passive avoidance tasks were added for mice at 24 weeks of age. Mice were sacrificed 
for biochemical analyses at 12, 18 and 24 weeks of age. (Sample size for each group was 8). Eight additional AD 
mice and eight wt mice were sacrificed at 8-weeks of age representing time 0 for biochemical and immuno-his-
tological analyses.
In a second experiment a new batch of both AD (n = 20) and wt (n = 20) animals has been treated with water 
(n = 10) or SLAB51 (n = 10) to perform the NOR test directly at 24 weeks of age. This second test was necessary to 
verify the hypothesis that 24-weeks-old mice could be saturated, and not motivated to explore any objects again, 
upon repeating the NOR for the fourth time.
Availability of data and material. The data that support the findings of this study are available from 
University of Camerino but restrictions apply to the availability of these data, which were used under license for 
the current study, and so are not publicly available. Data are however available from the authors upon reasonable 
request and with permission of the University of Camerino.
Experimental Procedures
Reagents and chemicals. SLAB51 formulation was provided by Mendes Sa (Lugano, Switzerland). 
Substrates for assaying the chymotrypsin-like (ChT-L), trypsin-like (T-L), and peptidyl glutamyl-peptide hydro-
lyzing (PGPH) activities of the proteasomal complex were purchased from Sigma-Aldrich S.r.L. (Milano, Italy). 
The substrate Z-Gly-Pro-Ala-Leu-Ala-MCA to test the branched chain amino acids preferring (BrAAP) activity 
was obtained from Biomatik (Cambridge, Ontario). Aminopeptidase N (EC 3.4.11.2) for the coupled assay uti-
lized to detect BrAAP activity36 was purified from pig kidney as reported elsewhere37. Cathepsin B and cathepsin 
L substrates (Z-Arg-Arg-AMC and Z-Phe-Arg-AFC.trifluoroacetate) were from Sigma-Aldrich S.r.L. (Milano, 
Italy). Membranes for western blotting analyses were purchased from Millipore (Milano, Italy). Proteins immo-
bilized on films were detected with the enhanced chemiluminescence (ECL) system (Amersham Pharmacia 
Biotech, Milano, Italy). p27 antibody was purchased from Calbiochem (EDM Millipore, Billerica, MA). All the 
other antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany). ELISA Kit for Aβ1–40 and Aβ1–42 
peptide determination in brain homogenates were purchased from Invitrogen (Camarillo, CA). Proteases inhibi-
tors tosyl phenylalanyl chloromethyl ketone (TPCK) and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochlo-
ride (AEBSF or Pefabloc) were from Sigma-Aldrich S.r.L. (Milano, Italy).
Animals. The triple-transgenic mouse model of AD, B6;129-Psen1tm1Mpm Tg (APPSwe,tauP301L)1Lfa/J 
(named 3xTg-AD) and their respective wild types mice were purchased from the Jackson Laboratory (Bar 
Harbor, Maine, USA). 3xTg-AD mice were previously characterized and represent a reliable model of human 
AD patients. In this model, Aβ intracellular immunoreactivity can be detected in some brain regions as early 
as three to four months of age38. Experiments were conducted using 8-week-old male mice (weight 15–25 g) in 
accordance with the guidelines laid down by the European Communities Council (86/609/ECC) for the care and 
use of laboratory animals. Mice were housed in plastic (Makrolon) cages (4 animals per cage) in a temperature 
controlled room (21 ± 5 °C) and 60% humidity on 12 h light/dark inverted cycle (light was switched on at 8:00 
P.M.) and maintained on laboratory diet (Mucedola, Italy) with water ad libitum. All appropriate measures were 
taken to minimize pain and discomfort in experimental animals. Brains, livers, feces and urines were properly 
stored at −80 °C after sacrifice.
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All procedures were in accordance with the guidelines laid down by the European Communities Council 
(86/609/ECC) for the care and use of laboratory animals under an approved protocol (EUFTP#261473) by 
Veterinary Health Dept. of the Italian Ministry of Health.
SLAB51 administration. Two groups of mice (n = 32 animals for each group) were treated for four months 
as follows: a 3xTg-AD group orally treated with vehicle (water), a 3xTg-AD group orally treated with SLAB51, a 
formulation made of nine live bacterial strains (Streptococcus thermophilus, bifidobacteria (B. longum, B. breve, 
B. infantis), lactobacilli (L. acidophilus, L plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus, L. brevis)). The 
dosage (200bn bacteria/Kg/day) was calculated by application of the body surface area principle39. Fresh drinking 
solution was changed every day. The body weight was measured every 2 weeks before starting the treatment and 
then once a month to ensure adequate intake of the experimental food.
Behavioral assessments. All behavioural experiments were performed during the animal’s dark phase, 
with testing performed from 8:00 to 15:00. Animals were handled for 3 days before testing in order to accustom 
them to the experimenter. The investigators were blinded to the groups’ allocation during the tests.
The open field (OF) test was used to evaluate the locomotor activity of mice using automated locomotor 
activity boxes (Med Associates, VT 05478) as previously reported40. Locomotor activity was recorded for 5 mins, 
starting 1 min after placing the animal in the test cage. Each mouse was automatically recorded by interruptions 
of orthogonal light beams (3.5 cm above the activity box floor), which were connected to automatic software 
(Activity Monitor, Med Associates). The behavioral parameters observed were ambulatory (number of horizontal 
episodes) and stereotype counts (number of grooming movements).
The novel-object recognition (NOR) test is used to evaluate recognition memory and it is based on the spon-
taneous tendency of rodents to spend more time exploring a novel object than a familiar one. Mice were chal-
lenged in the open-field arena explored on the day before during OF. Following a training period, the animal 
was removed from the environment for a delay period of 3 h and then it was returned to the arena, where one of 
the two identical objects had been replaced by a new, dissimilar novel object (test phase). The amount of time 
the rodent spends exploring each object in 10 mins provides a powerful measurement of memory integrity and 
attention.
Results were expressed as discrimination score (seconds spent with novel object − seconds spent with familiar 
object)/(total time spent with both objects). Lower score indicates memory impairment in this task. Objects were 
different for shape, color and texture at each time point41 and maintained throughout the study to obtain repro-
ducible data. Preliminary experiments were done to select novel and familiar object pairs on the basis that each 
object in the pairs elicited the same amount of spontaneous investigation.
The passive avoidance test is a fear-motivated test used to assess memory function based on the association 
formed between an aversive stimulus such as a mild foot shock and a specific environmental context. The amyg-
dala plays a pivotal role in passive avoidance learning.
Apparatus and procedures were previously described42. Briefly, during the training test, each mouse received 
an electric shock when it entered the dark compartment. In the retention test, passive defensive reactions, 
assessed in terms of the latent period of transfer from the light to the dark compartment, were tested 24 h and 7 
days after foot shock. Higher latency value translates to better retention of memory from the foot shock given 
during the learning phase43.
The elevated plus maze (EPM) is a test used to detect anxiety-related behavior in animals44. The apparatus, a 
cross-shaped wooden elevated maze, consisted of two opposite open arms 30 cm × 5 cm, and two opposite arms 
enclosed by 20-cm-high walls with two open arms and two closed arms. The maze was elevated 50 cm from the 
floor and lit by dim light. The procedure is described in Nasuti et al.45. Changes in the percentage of time spent 
and number of entries into the open arms indicate changes in anxiety-like behavior. A greater percentage of time 
spent and number of entries in open arms indicates less anxiety-like condition.
Microbiota analysis. An aliquot of 100 mg (wet weight) of each fecal sample DNA was extracted with a 
DNA isolation kit (MoBio Power soil, MoBio Laboratoroies, USA) following the manufacturer’s instructions. The 
V4 region of the 16S rRNA gene was amplified with primers 515 F (5′-GTGCCAGCMGCCGCGGTAA-3′) and 
806 R (5′-GGACTACVSGGGTATCTAAT-3′) at the MR DNA Laboratory (Shallowater, TX, USA) as previously 
described46. The Nextera® DNA sample Preparation kit including sequencing adapters and sample specific bar-
codes was used to prepare a DNA library and sequenced at MR DNA on an Illumina MiSeq instrument.
The raw sequences obtained were analyzed using the software QIIME v.1.8. A total of 5,343,083 were obtained. 
Sequences were demultiplexed, low quality reads were filtered using default parameters, chimeras removed and 
sequences were then clustered into operational taxonomic units (OTUs) using an open-reference OTU pick-
ing protocol at the 97% sequencing identity level against the Greengenes47 database. For further analysis, each 
was rarefied to an even sequencing depth of 24,800 sequences to adjust for uneven sequencing depth across all 
samples. Observed species richness, Chao 1, and Shannon indexes were determined using QIIME. The soft-
ware PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) was used to 
make functional gene content predictions based on 16S rRNA gene data generated by all organisms found in the 
data and represented in the Greengenes phylogenetic tree of 16S rRNA gene sequences. Because most datasets 
did not meet the assumptions of normal distribution as assessed by the D’Agostino and Pearson normality test, 
non-parametric statistical tests were used. The Friedman test with Dunn’s post hoc test for repeated measures 
ANOVA was performed to evaluate changes among all timepoints. The resulting p-values were adjusted for mul-
tiple comparisons using the Benjamini & Hochberg’s False Discovery Rate (FDR), and an adjusted p < 0.05 was 
considered statistically significant. Data were analyzed using Prism software 5.0 (GraphPad Software, San Diego, 
CA) and JMP software (SAS Institute, Cary, NC, USA). Linear discriminant analysis effect size (LEfSe), freely 
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available online in the Galaxy workflow framework, was used to elucidate taxa and genes associated with treat-
ments at the various time-points. Analysis of beta-diversity was performed using unweighted Unifrac distance 
metrics. Statistical significance of the resulting distance metric was tested by analysis of similarities (ANOSIM) 
using the QIIME software. Sequences were deposited in the SRA archive under the accession number: SRP064106. 
The software PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) was 
used to predict the functional gene content in the fecal microbiome based on the 16S rRNA genes found in the 
data and represented in the Greengenes phylogenetic tree of 16S rRNA gene sequences. PICRUSt was used online 
in the Galaxy workflow framework. Linear discriminant analysis effect size (LEfSe) was used to elucidate bacterial 
taxa (16S rRNA genes) and functional genes (PICRUSt) associated with healthy or diseased cats.
Short chain fatty acids (SCFAs) determination. Fecal content of acetic, propionic and butyric acid has 
been quantified by means of headspace solid-phase microextraction coupled to gas chromatography with flame 
ionization detection by using a polydimethylsiloxane/carboxen/divinyl benzene coated fiber, following the proce-
dure by Fiorini et al.48. Data are expressed as mean content (mmol/Kg) ± SD and were statistically analyzed using 
one-way analysis of variance, followed by the Tukey-Kramer method for post-hoc analysis. Different superscript 
letters (a, b) indicate significant variations at P < 0.05 in the table.
ELISA assay for ghrelin, leptin and GIP, GLP-1. Plasma hormone concentrations were measured 
through ELISA using plasma treated with protease inhibitors (Pefabloc and TPCK).
Briefly, the Rat/mouse Ghrelin Active ELISA kit is a sandwich ELISA based on the capture of ghrelin mole-
cules (active form) in the plasma by anti-ghrelin IgG and the immobilization of the resulting complex to the wells 
of a microtiter plate coated by a pre-titered amount of anchor antibodies. After the binding of a second biotiny-
lated antibody to ghrelin and the wash away of unbound materials, followed by conjugation of horseradish perox-
idase to the immobilized biotinylated antibodies, the quantification of immobilized antibody-enzyme conjugates 
is performed by monitoring horseradish peroxidase activities in the presence of the substrate 3,3′,5,5′-tetra-m
ethylbenzidine. The enzyme activity is measured spectrophotometrically by the increased absorbency at 450 nm, 
corrected from the absorbency at 590 nm, after acidification of formed products. Since the increase in absorbency 
is directly proportional to the amount of captured rat/mouse ghrelin (active form) in the unknown sample, the 
concentration of active ghrelin can be derived by interpolation from a reference curve generated in the same assay 
with reference standards of known concentrations of rat/mouse ghrelin.
Leptin and GIP were determined using sandwich ELISA kit based on anti-leptin and anti-GIP monoclonal 
antibodies respectively.
Similarly, the quantitative determination of mouse glucagon like peptide-1 was performed using a sandwich 
ELISA kit (CUSABIO Cat #CSB-E08118m). Antibody specific for GLP-1 was pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any GLP-1 present is bound by the immobilized antibody. 
After removing any unbound substances, a biotin-conjugated antibody specific for GLP-1 is added to the wells. 
After washing, avidin-conjugated horseradish peroxidase is added to the wells. Following a wash to remove any 
unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to 
the amount of GLP-1 bound in the initial step. The color development is stopped and the intensity of the color is 
measured.
Cytokine analyses. The plasma levels of pro- and anti- inflammatory cytokines were measured through 
ELISA using the Mouse Inflammatory Cytokines & Chemokines Multi-Analyte ELISArray Kit (QIAGEN, Italy). 
Samples and standards were prepared following the manufacturer’s protocols. Each cytokine level was calculated 
based on its own standard curve and expressed as mean concentration (pg/ml) ± SE.
Congo red staining and immunohistochemistry analysis. Three 3 μm-thick parasagittal sections 
from each animal (n = 8 per sub-group), at ~0.84, 1.20, and 1.56 mm lateral from the midline49, were prepared. 
Selected sections were deparaffinized and rehydrated according to standard protocols, and they were used for 
Congo red staining and for Aβ and FGF9 immunohistochemical detection. Hematoxylin and eosin counterstain-
ing was used to provide morphological details.
In detail, Aβ peptides were immunodetected using a polyclonal antibody with specificity for the Aβ1–42 
C-terminus (Millipore, CA). Briefly, for each time point (8, 12, 18, 24 weeks of age), brain slides from treated 
and untreated wt and AD mice (n = 8 per subgroup) were fixed in a 50:50 mixture of methanol and acetone for 
5 min and incubated with the anti-Aβ1–42 antibody (1:50). The binding of the antibody was detected with the Elite 
kit (Vector Laboratories), and the immunoreaction was developed using diaminobenzidine chromogen (DAB, 
Vector).
For FGF9 detection, brain sections were incubated overnight with anti-FGF9 rabbit polyclonal anti-
body (aa50–99) IHC-plus™ (LSBio Catalog No. LS-B11953), diluted 1:50, cross reacting with mouse, human, 
bovine and other animal species. Non-specific binding was blocked by incubation of slides for 10 minutes with 
a protein-blocking agent (Protein-blocking agent, Dako, Carpinteria, CA, USA) before application of the pri-
mary antibody. Slides were incubated overnight in a moist chamber. The immunoreaction with streptavidin–
immunoperoxidase (Streptavidin–immunoperoxidase, Black & Decker, Towson, MD, USA) was visualized with 
3,3′-diaminobenzidine substrate (3,3′-diaminobenzidine substrate, Vector, Burlingame, UK). Tissues were coun-
terstained with Mayer’s hematoxylin. For negative immunohistochemical controls the primary antibodies were 
omitted. Sections of human and bovine brain, AD and BSE respectively affected, served as positive control tissues 
for Aβ1–42 and FGF9 cell staining. For scoring of Congo red, Aβ1–42, and FGF9 positive cells, these cells were 
quantified in different area of the mouse brain, particularly select compartments of the CNS as hippocampal 
area. All cellular types were evaluated using a light microscope (Carl Zeiss, Jena, Germany), a 40x objective, a 
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10x eyepiece, and a square eyepiece graticule (10 × 10 squares, having a total area of 62,500 μm2). Ten appropriate 
fields were chosen for each compartment and arithmetic means were calculated for each brain region. Results 
were expressed as IHC positive cells per 62,500 μm2. For all parameters, cells on the margins of the tissue sec-
tions were not considered for evaluation to avoid inflation of positive cell numbers. Positive Congo red/Aβ1–42/
FGF9 cells, amyloid interstitial plaques, and other CNS areas, were quantified by using an image-analysis system 
consisting of a light microscope (Carl Zeiss, Jena, Germany) attached to a Javelin JE3462 high-resolution camera 
and a personal computer equipped with a Coreco-Oculus OC-TCX frame grabber and high-resolution monitor. 
Computerized color-image analysis was performed by using Image-Pro Plus software (Media Cybernetics). The 
entire cerebral cortex and hippocampus were separately sampled with the counting frame size 250 μm × 250 μm 
for cortex and 100 μm × 100 μm for hippocampus. The area of each section in all cross brain sections in every 
mouse was recorded, as was the total number of neurons determined by immunostaining as previously described. 
For each mouse, the total brain area was calculated as the sum of the areas of all fields in all brain cross sections 
on one slide. Congo red, Aβ1–42, and FGF9 positive cells were counted per section, and stained cell densities were 
expressed as the number of cells per square millimeter of analyzed section area24. The sum of the area of all amy-
loid plaques was divided by the total area of cerebral cortex or hippocampus to obtain the amyloid burden. The 
pathologist performing quantification of amyloid burden was blind to age, treatment type, and genotype of mice. 
The unbiased stereological based quantification of amyloid burden was performed on the basis of methodology 
suggested by Liu et al.50.
Measurement of the cortex. For the thickness measurement of the cortex wall, serial sections, in the cor-
onal plane, from rostral to caudal of each mouse cerebrum were made. Briefly, the brains were removed, placed in 
10% buffered formalin, covered with aluminum foil, and refrigerated. Two-mm-thick sections were cut 4, 6, and 
8 mm from the frontal pole, and sections were photographed within 24 h. To prevent distortion, brain slices were 
kept flat in the Petri dish overnight. After the sections had been photographed, they were routinely processed and 
paraffin embedded, then newly 3 µm sectioned and stained with hematoxylin and eosin (H&E) and newly pho-
tographed. The serial sections were sub-divided into frontal, parietal, temporal, and occipital regions of the brain 
in rostral to caudal direction. Qualitative and quantitative analyses of the wall of the cerebral hemisphere were 
carried out on every 20th section. For each sub-group, 5 sections were analyzed. In each of these coronal sections, 
brains were stained with H&E and the cortex thickness was measured. For the assessment of regional cortical 
atrophy the thicknesses of the wall and laminae was determined by thickness measurements on H&E-stained 
sections. The different zones were measured using a calibrated integrating graticule (0.01mm) in a single eyepiece. 
The method of point counting was used to determine the relative volume proportion of the cerebral wall, menin-
ges and ventricles. The same stratified selected sections were projected onto a screen using a Leitz demonstration 
microscope (x2.5). A grid with 300 points was superimposed on the image. The points falling on the cerebral 
wall, meninges, and ventricle were counted field-by-field to cover the entire left and right cerebral hemispheres.
Ventricular sizes evaluation in the brain sections. Equivalent sections of 3xTg-AD, and wild-type mice 
brains were chosen on the basis of common morphological landmarks49. Images of stained tissues were converted 
into TIFF format using Adobe Photoshop Elements 2.0. The areas of the brain substance and ventricles were 
measured using NIH ImageJ 1.39 u. Two images from each individual mouse were considered.
TUNEL analysis. In brain sections, apoptotic index was highlighted through a TUNEL colorimetric staining 
(DeadEnd, Promega®) according to the manufacturer’s instructions. For evaluation of the apoptotic rate, ten ran-
dom fields of any chamber were examined under a dry- 40x objective. TUNEL-positive cells are characterized by 
a brownish-black nuclear stain. Lower-power digitized images were acquired with a light microscope (Carl Zeiss, 
Jena, Germany) attached to a Javelin JE3462 high-resolution camera and a personal computer equipped with a 
Coreco-Oculus OC-TCX frame grabber and high-resolution monitor, and cells count and quantification were 
performed as previously reported.
Preparation of brain extracts. Brain extracts were homogenized (1:5 weight/volume of buffer) in 50 mM 
Tris buffer, 150 mM KCl, 2 mM EDTA, pH 7.5. Homogenates were immediately centrifuged at 13.000 × g for 
20 min at 4 °C and the supernatant was collected for enzymes activity assays and western blotting. A small part of 
this supernatant fraction was immediately supplemented with protease inhibitors for hormones determination 
by ELISA as described below. Protein content was determined by the Bradford method51 using bovine serum 
albumin (BSA) as standard.
Proteasome activity assays. Proteasome peptidase activities in brain homogenates (supernatant 
fraction) were determined using synthetic fluorogenic peptides: Suc-Leu-Leu-Val-Tyr-AMC was used for 
ChT-L activity, Z-Leu-Ser-Thr-Arg-AMC for T-L activity, Z-Leu-Leu-Glu-AMC for PGPH activity, and 
Z-Gly-Pro-Ala-Phe-Gly-pAB for BrAAP activity52. The incubation mixture contained brain homogenates 
(15 μg total proteins), the proper substrate (5 μM final concentration) and 50 mM Tris–HCl pH 8.0, up to a 
final volume of 100 μL. Incubation was performed at 37 °C for 60 min and the fluorescence of the hydrolyzed 
7-amino-4-methyl-coumarin (AMC) and 4-aminobenzoic acid (pAB) was detected (AMC, λexc = 365 nm, 
λem = 449 nm; pAB, λexc = 304 nm, λem = 664 nm) on a SpectraMax Gemini XPS microplate reader. The 26S pro-
teasome ChT-L activity was tested including in the reaction mix 10 mM MgCl2, 1 mM dithiothreitol, and 2 mM 
ATP.
Cathepsin B and L. Cathepsin B and L proteolytic activities were measured following the protocol described 
by Tchoupè et al.53 using the fluorogenic peptides Z-Arg-Arg-AMC and Z-Phe-Arg-AFC, respectively, at a final 
concentration of 5 μM. The mixture for cathepsin B, containing 7 μg of protein lysate, was pre-incubated in 
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100 mM phosphate buffer pH 6.0, 1 mM EDTA and 2 mM dithiothreitol for 5 min at 30 °C. Upon the addition 
of the substrate, the mixture was incubated for 15 min at 30 °C. The mixture for cathepsin L, containing 7 μg of 
protein lysate, was incubated in 100 mM sodium acetate buffer pH 5.5, 1 mM EDTA and 2 mM dithiothreitol for 
5 min at 30 °C and, upon the addition of the substrate, the mixture was incubated for 15 min at 30 °C. The fluo-
rescence of the hydrolyzed 7-amino-4-methyl-coumarin (AMC, λexc = 365 nm, λem = 449 nm) and 7-amino-4
-trifluoromethylcoumarin (AFC, λexc = 397 nm, λem = 500 nm) was detected on a SpectraMax Gemini X PS 
microplate reader.
Western blotting analyses. Brain homogenates (supernatant fraction) were analyzed through western 
blotting assays with the aim to measure the following intracellular protein levels: amyloid oligomers, ubiquiti-
nated proteins, p53, p27 and the autophagy related proteins Beclin-1, p62 and LC3-II. In detail, for each time 
point brain homogenates (20 μg total protein) were loaded on 12% SDS-PAGE (15% for LC3; 10% for ubiquiti-
nated proteins and amyloid oligomers) and electroblotted onto PVDF membranes. Successively, upon incubation 
with specific antibodies, the immunoblot detections were carried out with Enhanced ChemiLuminescence west-
ern blotting analysis system (Amersham Pharmacia-Biotech). Molecular weight markers (6.5 to 205 kDa) were 
included in each gel. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to check equal protein 
loading. The bands were quantified by using a densitometric algorithm. Each Western Blot was scanned (16 bits 
greyscale) and the obtained digital data were processed through Image J (NIH)54 to calculate the background 
mean value and its standard deviation. The background‐free image was then obtained subtracting the back-
ground intensity mean value from the original digital data. The integrated densitometric value associated to each 
band was then calculated as the sum of the density values over all the pixels belonging to the considered band 
having a density value higher than the background standard deviation. The band densitometric value was then 
normalized to the relative GAPDH signal intensity. The ratios of band intensities were calculated within the same 
Western Blot. All the calculations were carried out using the Matlab environment (The MathWorks Inc., MA, 
USA)55.
ELISA assay for Aβ levels determination. Brain homogenates (supernatant fraction) promptly sup-
plemented with protease inhibitors (Pefabloc and TPCK) were used to measure Aβ1–40 and Aβ1–42 levels using 
enzyme-linked immunosorbent assay NOVEX® ELISA kits (Invitrogen,). Based on preliminary tests, samples 
were diluted at 1:5 with diluent buffer provided by the kit. Assays were performed according to the manufacturer’s 
directions.
Statistical analysis. Results of behavioral tests were expressed as mean ± S.E. In particular, the EPM was 
analyzed by mean of Student’s t test. For the OP, NOR and passive avoidance, a two-way ANOVA with one factor 
within (time) and one factor between (treatment) was employed and appropriate post-hoc analysis was carried 
out using the Newman-Keuls test. Biochemical and IHC data are expressed as mean values ± S.E. Statistical anal-
ysis was performed with one way ANOVA, followed by the Bonferroni test using Sigma-stat 3.1 software (SPSS, 
Chicago, IL, USA). P-Values p < 0.05 were considered to be significant.
Results
Administration of SLAB51 counteracts cognitive decline and brain damage in AD mice. The 
effect of the probiotic on the consolidation process of memories in AD mice was assessed through the novel 
object recognition (NOR) and the passive avoidance tests, which have been used as cognitive probes for detecting 
hippocampus and amygdala functions, respectively.
In a first experiment, the AD mice were submitted to the NOR test at all time points (weeks 8, 12, 18 and 24) 
and differences between treated and control mice were observed (F[1,28] = 6.8, p < 0.05) as shown in Fig. 1, panel 
A. In particular, AD mice treated with the probiotic showed better “discrimination index” than untreated animals 
at 18 weeks of age, suggesting the beneficial effect of SLAB51 after 10 weeks of treatment. However, we could not 
see differences between 24-week-old treated and untreated mice. It is likely that mice may be not motivated to 
explore any objects again, regardless of whether they are familiar or novel. Indeed, compared to 18-week-old mice 
(25 s and 19 s for treated and untreated mice, respectively), the 24-week-old ones spent significantly less total time 
exploring both objects during the test phase (16.8 s and 9.6 s for treated and treated mice, respectively). To verify 
this hypothesis, a second group of AD and wt mice were submitted to the NOR test at only two time points (weeks 
8 and 24). Here, we could appreciate differences between treated and untreated AD mice when they were 24 weeks 
old (F[3,40] = 2.95, p > 0.05) as shown in Fig. 1, panel B. In particular, treated AD mice showed an improvement 
in cognitive performance compared to age-matched untreated AD mice, demonstrating a sustained beneficial 
effect of SLAB51 until 24 weeks of age. No significant differences were observed between treated wt mice and 
age-matched untreated wt mice.
In the first experiment, 24-week-old treated and untreated AD mice underwent the passive avoidance test. 
Statistical analysis computed on passive avoidance behavior of AD mice showed no significant differences in the 
test performed at 24 h and 7 days (F[1,27] = 0.55, p > 0.05) after the training test, whereas a significant effect of 
time (F[2,54] = 117.84, p < 0.05) was observed (data not shown). However, higher entry latencies near the cut-off 
value (300 s), measured in the retention test, demonstrated that AD mice were able to memorize the punishment 
and to perform the inhibitory avoidance, indicating that triple mutation did not impair amygdala function.
24-week-old treated and untreated AD mice, from the first experiment, were evaluated in the elevated plus 
maze (EPM) to analyze their anxiety-like behavior. Statistical tests computed on the % open arm entries (df = 28, 
t = 0.30, p > 0.05) and on the % time spent in the open arms (df = 28, t = −1.08, p > 0.05) revealed no signif-
icant between-group differences, reflecting the same level of anxiety-like responses in treated and untreated 
age-matched AD mice (Fig. 1, panel C).
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Figure 1. SLAB51 ameliorates behavioral performance and reduces brain damage in AD mice. Novel Object 
Recognition (NOR) test (first experiment): 15 mice/sub-group were allowed to explore an identical pair of 
objects, and after 3 hours, they are presented with the familiar object and a novel object. The discrimination 
scores for 8, 12, 18, and 24-week-old AD mice are reported in panel A. NOR test (second experiment) 
performed for the first time on treated and untreated 24-week-old mice (groups’ size = 10), panel B. Panel C: 
Elevated plus maze test. % open arm entries and % time spent in the open arms by untreated and treated AD 
mice at 24 weeks of age (first experiment, groups’ size = 15). Data points marked with an asterisk are statistically 
significant compared to their respective non-treated control mice (*p < 0.05). Panel D Immunodetection of 
FGF9 protein in brain slides of 24-weeks old untreated and treated wt and AD mice (8 animals per group) 
from the first experiment. Results are reported as number of cells immunoistochemically positive for FGF9 
per field ± ES (#statistically significant with respect to the corresponding untreated mice p < 0.05). For 
each histological section 5 randomly selected field were analyzed at 40xHPFs. Representative images of 
immunohistochemical staining are reported. Panel E: Brain weights expressed in grams ± ES of both treated 
and untreated wt and AD mice over time (groups’ size is 8). Panel F: Measurement of the cortex thickness (mm) 
and ventricular sizes evaluation (mm3) in the brain sections of control and SLAB51 treated AD mice at 8, 12, 18 
and 24 weeks of age. Data are reported as mean values ± ES (*statistically significant with respect to 8 weeks-old 
untreated mice p < 0.05; #statistically significant with respect to the corresponding untreated mice p < 0.05). 
Consecutive brain slides of treated and untreated 24 weeks-old AD mice are shown.
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To verify that the beneficial effects of SLAB51 on attenuating cognitive impairment were not linked to an 
increased locomotor activity, AD mice (from the first experiment) were evaluated in an open field (OF) test at 
each time point (weeks 8, 12, 18 and 24). Two-way ANOVA revealed no differences in locomotor activity between 
treated and control AD groups (ambulatory counts: F[1,28] = 0.116, p > 0.05; stereotypic counts: F[1,28] = 1.95, 
p > 0.05) as shown in Table 1. These data suggested that SLAB51 treatment did not influence the locomotor activ-
ity of AD mice. Together, these findings rule out the possibility that, in the NOR, the different response between 
treated and control AD mice could depend upon differences in locomotor activity.
These results are consistent with the expression levels of FGF9 in the hippocampal areas of 24 week-old mice 
(4 months of treatment), as reported in Fig. 1, panel D. Based on published data indicating that specific growth 
factor transcripts are altered in depressed, stressed, and AD-affected brains56–58, we selectively examined FGF9 
differential expression in AD and wt mice. Results indicate a significant difference in FGF9 expression between 
treated and untreated AD mice, and a similar level and pattern of expression between treated AD and control 
wt mice. In fact, hippocampal FGF9 expression was consistently increased in untreated AD mice compared to 
treated AD and control wt mice. Thus, these analyses confirmed the alteration of FGF9 in depressive disorders, 
and show also its up-regulation in the altered hippocampus of AD-affected mice. Few studies have previously 
demonstrated the increased FGF9 expression in the frontal cortices56 and locus coeruleus57 in patients with major 
depression. Moreover, so far no data are available on the role of FGF9 in the hippocampus during AD or its role in 
the regulation of emotionality. Thus, our results could be helpful in elucidating the potential role of the hippocam-
pal FGF9 in conditioning emotions and behavioral performances in AD.
The body weight of mice was controlled during the entire period of treatment and no differences were 
obtained between control and AD animals, indicating that the mixture was well tolerated. Interestingly, the brain 
weight of SLAB51-treated mice showed no changes, whereas in control animals a significant decrease over time 
was observed (Fig. 1, panel E).
Regarding brains morphology, it was immediately apparent that lateral ventricles were enlarged in 3 × Tg-AD 
untreated mice compared with SLAB51 treated animals (Fig. 1, panel F). In some areas of the brain, notable 
differences in the cortex thickness were observed between treated and untreated AD mice. Differences in thick-
ness of the cerebral cortex were also minimal at t0 (8 weeks-old) and t1 (12 weeks-old), though the ventricular 
zone appeared slightly enlarged in untreated AD mice. Starting from t2 (18 weeks-od), the difference in cortical 
thickness became more pronounced between the two groups (Fig. 1, panel F) in particular in the hippocampal 
area (bregma −2.18 mm), at level of interventricular foramem (bregma −0,22 mm), and lateral ventricle at the 
point of alignment with the anterior arm of corpus callosum (bregma 0.62 mm). These data suggest the beneficial 
effect of SLAB51 in counteracting the decline of cortical thickness and the ventricular dilatation that are typical 
damages in AD brains.
SLAB51 modifies intestinal microbiota. PCoA plots of unweighted Unifrac distances revealed signifi-
cant differences in microbiota structure between the wt and 3xTg-AD mice at all time points, but no significant 
differences were observed in species richness between wt and AD mice (Fig. 2). Considering untreated mice, 
lower concentrations of Tenericutes, Cyanobacteria, Anaeroplasmatales, and Anaerostipes were present in AD 
mice with respect to wt mice, with Anaerostipes playing an important role in gut health for the ability to pro-
duce butyric acid59 (Supplemental Table S1). Furthermore, the microbiota structure underwent more changes 
over the various time points in the 3xTg-AD, as the distances in the PCoA plots were larger, while the dis-
tances between the weeks clustered closer together in the wt mice. Moreover, treatment with SLAB51 induced 
larger changes in AD mice compared to wt mice. However, after adjustment for multiple comparisons, only a 
few bacterial taxa were found to be significantly different when either group of mice were or were not treated 
with SLAB51 (Supplemental Tables S2 and S3). Overall, similar changes in specific taxa were observed between 
the animal groups, and most notably, an increase in Bifidobacterium spp. and a reduction in Campylobacterales 
(i.e., Helicobacteriaceae; p = 0.04) was observed in both mouse groups when treated with SLAB51. The pre-
dicted functional bacterial metagenome content using PICRUSt revealed different effects of SLAB51 between 
wt and 3xTg-AD mice. While 14 pathways were increased (LDA score >4.0) due to SLAB51 in the 3xTg-AD 
mice, only one pathway was increased in wt mice (Table 2). SLAB51 induced several metabolic pathways in the 
3xTg-AD mice, including DNA repair, pyrimidine metabolism, transcription machinery, energy metabolism, and 
glycolysis-gluconeogenesis.
Additionally, the fecal content of SCFAs was evaluated considering that these bacterial byproducts are known 
to act on the brain and that may mediate the effect on AD pathology. Interestingly, Table 3 shows that acetic, 
Weeks 8 12 18 24
Ambulatory counts
AD control 571 ± 52.82 340 ± 55.16 384 ± 10.48 297 ± 8.53
AD + SLAB51 556 ± 80.92 367 ± 49.19 351 ± 14.55 298 ± 15.31
Stereotypic counts
AD control 416 ± 12.60 378 ± 18.69 350 ± 13.60 313 ± 20.58
AD + SLAB51 410 ± 13.93 343 ± 21.83 325 ± 20.67 302 ± 19.47
Table 1. SLAB51 effect on locomotor activities. Open Field test. Locomotor activities were registered after 
5 mins. Ambulatory and stereotypic counts are expressed as means ± SEM. Group sizes: AD control (n = 15), 
AD + SLAB51 (n = 15). (p > 0.05).
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propionic and butyric acids significantly increased in AD mice upon SLAB51 treatment. Considering that the 
composition of gut microbiota and its metabolites can influence the inflammatory signaling, a panel of pro- and 
anti- inflammatory cytokines has been evaluated in the plasma of both wt and AD mice administered with water 
or SLAB51.Upon SLAB51 administration reduced plasma concentrations of pro-inflammatory cytokines have 
been observed in AD mice (Fig. 3), confirming that the modified microbiota produced anti-inflammatory effects. 
In detail, higher plasma concentrations of pro-inflammatory cytokines such as IL1α, IL1β, IL2, IL12, IL17, IFNɣ, 
and TNFα were observed in untreated AD mice with respect to wt counterpart. Interestingly, upon SLAB51 
treatment a significant decrease of IL1α, IL1β, IL2, IL12, IFNɣ, and TNFα occurred. Moreover IL4, IL6, G-CSF, 
and GM-CSF, are less concentrated in the plasma of untreated AD mice with respect to wt mice. The probiotic 
treatment resulted in an increase of these cytokines that can down-regulate inflammatory response60. Collectively, 
these data are in agreement with the enriched gut content of the recognized anti-inflammatory SCFAs in AD mice 
upon probiotics supplementation.
Increased gut hormone concentration with SLAB51 treatment. We measured the plasma concen-
tration of the gut peptide hormones ghrelin, leptin, GLP-1 and GIP because of their neuroprotective effects and 
potential as therapeutic targets. No changes in hormone plasma levels were observed in treated wt mice compared 
to the respective controls. An age-dependent decrease of the levels of all the tested hormones was observed in 
untreated AD mice. Interestingly, treatment with the probiotic formulation specifically increased the plasma 
concentration of these hormones. Results indicate significantly increased levels of ghrelin and GIP in 18- and 
24-week-old treated AD mice compared to their respective controls. The level of leptin upon SLAB51 administra-
tion increased in treated 24-week-old AD mice compared to untreated animals. Treatment with SLAB51 induced 
an increase in GLP-1 plasma concentration by 12 weeks of age (Fig. 4).
SLAB51 decreased amyloid load in AD mice brain. To assess if SLAB51 treatment had effects on brain 
Aβ load, we first measured the levels of Aβ1–40 and Aβ1–42 peptides. As expected, amyloid peptides did not increase 
in wild type mice (data not shown), Interestingly, Aβ1–42 load was significantly reduced in 12-week-old AD mice 
treated with SLAB51 compared to controls. No significant effect on Aβ1–40 levels was observed (Fig. 5, panel A). 
We then evaluated the accumulation of amyloid oligomers through western blotting and found a considerable 
Figure 2. Microbiota analysis. PCoA plots based on unweighted Unifrac distances and rarefaction curves are 
presented. The microbiota was analyzed using 16S rRNA gene sequencing. PCoA plots based on unweighted 
Unifrac distances reveal separation between the microbiota of wt and AD mice at all time points, indicating 
that the affected mice have different microbiota structure compared to wt mice. No significant differences 
were found in alpha diversity indices, revealing no difference in species richness. The progression over time 
from week 8 to week 24 was more pronounced in the AD mice compared to the wt mice. Also, treatment with 
SLAB51 induced larger changes in AD mice compared to wt mice, but no differences in species richness (t0 = 8 
weeks; t1 = 12 weeks; t2 = 18 weeks; t3 = 24 weeks).
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reduction of these toxic structures in treated AD mice, at both 18 weeks and 24 weeks of age, compared to con-
trols (Fig. 5, panel B). Congo red staining of brain Aβ plaques evidenced a significant reduction of extracellular 
amyloid deposits, associated with substantially lower levels of staining of somata and processes of hippocampal 
pyramidal cells from Ammon’s horn, and in granule cells from dentate gyrus, especially in sections of AD mice 
treated with the SLAB51 mixture (Fig. 5, panel C). Regarding the effects of SLAB51 on wt animals, no significant 
changes in the amount of amyloid peptides were observed, as also demonstrated histologically in Congo red 
stained sections (Fig. 5, panel C). Moreover, immunoreactivity towards Aβ1–42 peptide was progressively seen in 
somata and processes of hippocampal pyramidal cells and cortical neurons of untreated AD mice. Lower amounts 
of Aβ1–42 deposits were immunodetected in SLAB51 treated AD mice (Fig. 5, panel D).
Effect of SLAB51 mixture on proteasomal and autophagic proteolytic activity. Brain homoge-
nates were analyzed through enzymatic assays and western blotting analyses in order to monitor the function-
ality and expression levels of components of the proteolytic pathways UPS and autophagy. In wt mice, SLAB51 
did not modify proteasome functionality at any time point. A different result was obtained when analyzing AD 
mice. In fact, proteasome activity decreased in 3xTg-AD control mice, whereas AD mice treated with SLAB51 
showed partially restored activity. In particular, 18- and 24-week-old treated AD mice showed increased ChT-L, 
T-L, and PGPH activity compared to age-matched untreated controls. A re-establishment of BrAAP activity was 
already evident at 12 weeks of age (Fig. 6). A similar pattern was obtained measuring the ChT-L activity of the 
26S proteasome, the complex in charge of the removal of ubiquitinated proteins, where a significant recovery of 
activity was evident in treated AD mice at each time point (Fig. 6). To confirm these data, we performed western 
blotting assays to detect p27, p53 and ubiquitinated proteins, known substrates of the proteasome and markers 
of its functionality. At the analyzed time points, treated and untreated wt mice showed no significant differences 
in the expression levels of these proteins (Fig. 7). As expected, AD mice displayed a considerable accumulation 
of the analyzed substrates due to the strong proteasome impairment typical of neurodegeneration61. Figure 6 
indicates that in AD mice, SLAB51 treatment induced a decrease in the levels of these markers in agreement with 
the data from the activity assays. The reduction in the buildup of ubiquitinated proteins induced by SLAB51 was 
significant in 18-week-old mice, whereas the effects on p27 and p53 were already evident in 12-week-old mice. 
The accumulation of these substrates, in particular p53, in treated and control AD mice, correlates with the signif-
icantly different apoptotic index at the neuronal level, especially in the granule cells layer from the hippocampal 
KEGG orthologs
LDA 
score Group
Two-component system 4.20 3xTg-AD not treated
Bacterial motility proteins 4.13 3xTg-AD not treated
Secretion system 4.10 3xTg-AD not treated
General function prediction only 4.55 3xTg-AD treated SLAB51
DNA repair and recombination proteins 4.47 3xTg-AD treated SLAB51
Pyrimidine metabolism 4.31 3xTg-AD treated SLAB51
Peptidases 4.30 3xTg-AD treated SLAB51
Chromosome 4.21 3xTg-AD treated SLAB51
Amino sugar and nucleotide sugar metabolism 4.17 3xTg-AD treated SLAB51
Ribosome biogenesis 4.15 3xTg-AD treated SLAB51
Methane metabolism 4.14 3xTg-AD treated SLAB51
DNA replication proteins 4.13 3xTg-AD treated SLAB51
Alanine aspartate and glutamate metabolism 4.06 3xTg-AD treated SLAB51
Energy metabolism 4.04 3xTg-AD treated SLAB51
Glycolysis-gluconeogenesis 4.02 3xTg-AD treated SLAB51
Transcription machinery 4.01 3xTg-AD treated SLAB51
Homologous recombination 4.01 3xTg-AD treated SLAB51
Function unknown 4.13 wt not treated
Other ion-coupled transporters 4.07 wt treated SLAB51
Table 2. Effects of SLAB51 on KEGG orthologs in 24 weeks old wt and 3xTg-AD mice.
Acetic acid Propionic acid Butyric acid Total SCFA
(mmol/Kg)
AD control 26.64a ± 5.66 8.53a ± 2.91 4.15a ± 4.15 39.31a ± 11.61
AD + SLAB51 42.62b ± 2.23 13.65b ± 3.30 15.52b ± 7.81 71.79b ± 12.03
Table 3. Short chain fatty acids (SCFA) fecal content (mmol/Kg) ± standard deviation in 24 weeks old 3xTgAD 
mice. Different letters within the same column indicate significant differences (P < 0.05, one-way analysis of 
variance and Tukey’s test for pairwise comparison).
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area of dentate gyrus (Fig. 8), and also in the pyramidal cells layer from Ammon’s horn of the hippocampal area. 
No statistically significant differences in apoptotic levels were observed in 24-week-old treated AD mice and 
in treated or control wt mice. The considerable accumulation of p53 due to the strong proteasome impairment 
observed in untreated AD mice confirms the ability of this substrate to trigger the apoptotic pathway; as expected, 
treatment with the probiotic mixture induced a considerable decrease in apoptotic activity, regulating the levels 
of proteasome substrates.
Among the lysosomal enzymes, cathepsin B and cathepsin L were evaluated. Cathepsin B (CatB) is a cysteine 
protease associated with amyloid plaques and suggested to reduce Aβ levels62. A decrease in Cathepsin B activity 
was observed in 18- and 24-week-old treated mice compared with controls. Conversely, SLAB51 was able to 
restore cathepsin L (CatL) activity in 18- and 24-week-old mice compared with controls (Fig. 9). This finding is of 
particular interest considering the ability of the enzyme to increase α-secretase activity, thereby suppressing Aβ 
levels63. Exposure to SLAB51 did not change the activity of either enzyme in wt mice.
The levels of the autophagy-related proteins beclin-1, LC3-II, and p62 were detected through western blotting 
assays. Beclin-1 plays a key role in autophagy, being involved in the enrolment of membranes to form autophago-
somes64. LC3-II is tightly bound to the autophagosomal membranes and is an established autophagic marker65. 
p62 binds to both LC3-II and ubiquitin, and is finally degraded in autophagolysosomes. Therefore, p62 levels 
inversely correlate with autophagic activity66. Our data show that in AD mice, treatment with SLAB51 increased 
the levels of beclin-1 and LC3-II and decreased the amounts of p62, suggesting an activation of the autophagic 
flux (Fig. 9).
Discussion
AD is a progressive neurodegenerative disorder, with age the major risk factor. AD patients are characterized by 
cognitive impairment and dementia, the accumulation of neurofibrillary tangles and Aβ senile plaques, neurite 
and brain cell atrophy, and increased oxidative stress and pro-inflammatory signals67, 68. Interestingly, the role of 
microbes in both aging and the onset and progression of AD has been emerging in recent years26, 69. In this regard, 
studies conducted on animal models showed that modifications of gut microbiota induced by oral bacteriother-
apy reflect changes in genes involved in inflammatory and neuronal plasticity processes, with a positive impact 
on neuronal function33, 70.
In the present work, we assessed the potential beneficial effects of modulating gut microbiota composition by 
a four-month treatment with SLAB51 (a mixture of lactic acid bacteria and bifidobacteria) in a triple transgenic 
mouse model of AD, 3x-Tg AD mice38, in the early stages of the disease.
Significant differences in microbiota structure were observed at all time points between the wt and the 
3xTg-AD mice, and these differences were independent of treatment. However, treatment with SLAB51 induced 
larger shifts in microbial communities in the 3xTg-AD mice, as evidenced by more pronounced changes in 
Unifrac distances. Interestingly, this did not lead to obvious differences in abundances of specific bacterial taxa, 
suggesting more gradual shifts across the entire microbiota. However, the functional content as predicted by 
PICRUSt was associated with more changes due to SLAB51 in AD mice, as more pathways were increased due 
to treatment. Of interest is that SLAB51 induced several metabolic pathways associated with energy metabolism, 
amino acid metabolism, and nucleotide metabolism.
The increase in Bifidobacterium spp. and the reduction in Campylobacterales observed in AD mice upon 
administration with SLAB51 is important for the role of these bacteria in inflammatory pathways. In fact, 
Bifidobacterium strains possess anti-inflammatory properties principally attributed to small heat-stable, 
non-lipophilic compounds resistant to protease and nuclease treatments71. Moreover, certain species of genus 
Figure 3. Inflammatory cytokines. ELISA of inflammatory cytokines measured in the plasma of 24 week-
old wt and AD mice untreated or treated with SLAB51. Analytes concentrations are expressed as mean ± SE. 
Data points marked with an asterisk are statistically significant compared to their respective untreated mice 
(*p < 0.05).
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Bifidobacterium could negatively modulate mRNA levels of pro-inflammatory cytokines produced from 
LPS-stimulated macrophages72. Instead, immune-stimulatory effects of Campylobacter jejuni and Campylobacter 
coli have been observed on peripheral blood mononuclear cells73. Additionally, in vivo studies demonstrated that 
the purified lipooligosaccharid of Campylobacter jejuni increased the expression of pro-inflammatory cytokines 
in chickens74. Upon SLAB51 administration reduced plasma concentrations of pro-inflammatory cytokines have 
been observed in AD mice (Fig. 3), confirming that modification of microbiota produced anti-inflammatory 
effects in probiotic administered subjects. Interestingly treated AD mice possess higher levels of G-CSF that is a 
modulator of systemic immune responses by inhibiting pro-inflammatory cytokines and has been demonstrated 
to decrease β-amyloid deposition and to reverse cognitive impairment in an AD mice model60.
Figure 4. Plasma concentrations of gut hormones. Hormones were determined in the plasma of treated and 
control wt and AD mice. Results are expressed as percentage with respect to 8 week-old untreated mice. Data 
points marked with an asterisk are statistically significant compared to 8 week-old untreated control mice 
(*p < 0.05). Data points marked with hash are statistically significant compared to their respective control mice 
in the same time point (#p < 0.05).
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Figure 5. Aβ load. Panel A: Aβ1–40 and Aβ1–42 levels expressed as pg/ml determined by ELISA in the brains of AD 
mice treated or not with SLAB51 (n = 8). Panel B: Expression levels of amyloid oligomers detected by western 
blot. The densitometry from five separate blots and a representative immunoblot are reported. Equal protein 
loading was verified by using an anti-GAPDH antibody. The detection was executed by ECL. Data points marked 
with an asterisk are statistically significant compared to 8 weeks-old controls (*p < 0.05). Data points marked 
with hash are statistically significant compared to their respective control mice in the same time point (#p < 0.05). 
Uncropped gels are reported in Supplemental Figure 1. Panel C: Congo red staining of extra- and intra-cellular 
amyloid deposits in 24-week-old wt and AD mice administered with water or SLAB51 (groups’ size is 8). Specific 
Congo red staining was progressively seen in somata and processes of hippocampal Ammon’s horn pyramidal 
cells (insert), especially in untreated AD mice. Strong extracellular deposits demonstrate the formation of amyloid 
plaques, also visualized by immunostaining. (Congo red stain, with Meyer’s hematoxylin nuclear counterstain. 
Coronal sections, Bar = 400 μm; dentate gyrus magnification, Bar = 200 μm; insert, Bar = 50 μm). Data are 
presented as positive cells/field and are representative of 5 histological section for each brain (n = 8 per sub-group). 
Data points marked with a hash are statistically significant compared to their respective water-treated mice 
(p < 0.05). Panel D. Aβ1–42 IHC stain: wt and AD mice administered with water (control) or SLAB51. In both upper 
(low magnification) and lower (high magnifications) groups of images, immunoreactivity towards Aβ1–42 peptide 
(Aβ1–42 C-terminus pAb, Millipore) was progressively seen in somata and processes of hippocampal pyramidal 
cells and cortical neurons of AD untreated mice. A strong extracellular reactivity, associated with Aβ plaque 
formation, can be observed in both treated and untreated AD mice (IHC stain, with Meyer’s hematoxylin nuclear 
counterstain. Coronal sections, Bar = 400 μm; dentate gyrus magnification, Bar = 200 μm). The histogram shows 
the Aβ1–42 positive cells/field. Data represent 5 histological section for each brain (n = 8). Data points marked with 
a hash are statistically significant compared to their respective water-treated mice (p < 0.05).
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Figure 6. Effect of SLAB51 on proteasomal activity. Proteasome activity in SLAB51 treated and untreated 
wt (left) and AD (right) mice. The ChT-L, T-L, PGPH and BrAAP activities of the 20S proteasome and the 
ChT-L activity of the 26S proteasome were measured in brain homogenates as described in the Methods 
section. Results are expressed as fluorescence units (U. F.). Data points marked with an asterisk are statistically 
significant compared to untreated 8-week-old mice (*p < 0.05). Data points marked with a hash are statistically 
significant compared to their respective control mice in the same time point (*p < 0.05).
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Behavioral tests highlight a positive effect of oral treatment with SLAB51 on behavioral performance in AD 
mice, suggesting the restoration of hippocampus functions, in agreement with published evidence supporting 
the idea that cognitive functions are affected by bacteria acting through the gut-brain axis. Some authors have 
demonstrated that certain strains of Lactobacillus and Bifidobacterium secrete essential neurotransmitters such as 
gamma-aminobutyric acid (GABA) and acetylcholine that mediate the positive impact of probiotics on behavior 
in neurological dysfunctions75. Additionally, an impact on anxiety of Campylobacter jejuni infection has been 
previously reported in central nervous system disorders76. In our study, the improved cognitive activity in treated 
AD mice did not correlate with different levels of anxiety. Interestingly, analysis of microbiota showed a reduced 
presence of Campylobacterales in the treated AD group compared with the untreated AD group (Supplementary 
Table 2). This result is valuable also considering that a high prevalence of Campylobacterales infections have been 
observed in AD patients and, after Helicobacter pylori eradication, cognitive and functional status parameters 
ameliorated77.
Improvement of cognitive function is supported by increased plasma concentration of gut hormones such as 
ghrelin, leptin, GLP1 and GIP. Peptide hormones secreted in the gut play a role in modulating nervous functions 
like learning and memory. The time-dependent decrease of both ghrelin and leptin plasma concentrations in AD 
mice are in agreement with previously published data showing altered peripheral levels of these hormones in AD 
patients8, 78. Moreover, some authors previously demonstrated 3–4 months-old male 3xTg-AD mice exhibit sig-
nificantly higher basal mineralocorticoids and glucocorticoids mRNA levels in the hippocampus and increased 
glucocorticoids but decreased corticotrophin releasing hormone mRNA levels in the paraventricular nucleus of 
the hypothalamus compared to male WT mice79. Thus, the progressive decrease of circulating metabolic hor-
mones concentration in untreated AD mice may be due to the unbalanced hypothalamic-pituitary-adrenal axis. 
In fact, these hormones are affected by several factors such as stress, and glucocorticoids levels80. Interestingly, 
mice treated with the probiotic mixture showed higher plasma levels of such hormones, and this is important 
because ghrelin has been proven to counteract memory deficits and synaptic degeneration in AD animal models9, 
and leptin has been demonstrated to act as neurotrophic factor and to exert neuroprotective effects against 
Figure 7. Effect of SLAB51 on proteasomal substrates. Detection of the levels of ubiquitinated proteins (panel 
A), p27 (panel B) and p53 (panel C) in SLAB51 treated and untreated wt and AD mice. The densitometric 
analyses obtained from five separate blots and representative immunoblots are shown. Equal protein loading 
was verified by using an anti-GAPDH antibody. The detection was executed by an ECL western blotting analysis 
system. Data points marked with an asterisk are statistically significant compared to 8-week-old control mice 
(*p < 0.05). Data points marked with a hash are statistically significant compared to their respective control 
mice at the same time point (#p < 0.05). Uncropped gels are reported in Supplemental Figure 1.
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toxicity induced by Aβ oligomers in vitro5, 6. These data correlate with the decreased Aβ deposits in the brains 
of treated AD mice, and they are in good agreement with evidence showing that plasma leptin concentration is 
negatively associated to Aβ levels due to a direct regulatory effect on the γ-secretase-mediated amyloidogenic 
pathway10. The age-related decline of plasma ghrelin concentration and the impairment of ghrelin signaling 
observed in AD patients are closely related to the compromised memory and learning processes. Oral adminis-
tration of SLAB51 enhanced GLP-1 and GIP plasma concentrations in AD mice, resulting in a neuroprotective 
effect of both incretins81. Again, GLP-1 has been shown to reduce Aβ load in vivo and in cultured neuronal cells14. 
Interestingly, following SLAB51 administration an increase of the bacterial metabolites SCFAs has been detected 
in feces of AD mice. Considering that bacterial by products such as SCFAs exert a number of neuromodulator 
effects and directly act on gastrointestinal cells stimulating the synthesis of hormones like leptin and GLP-134, our 
data contribute to define the link between gut microbiota modulation and metabolic hormones. Moreover, the 
enriched gut concentration of SCFAs, well recognized anti-inflammatory bioactive metabolites82, 83 is encouraging 
also because of the number of evidences supporting SCFAs therapeutic potential in neurodegenerations84. For 
example, histone deacetylase inhibitor 4-phenylbutyrate is responsible for restoring fear learning, counteracting 
intraneuronal Aβ deposition, and regulating dendritic spine density by exerting a chaperone-like activity and via 
the transcriptional activation of key proteins in synaptic plasticity and structural remodeling85; Here we show that 
SLAB51 administration exerts multiple effects by modulating gut microbiota composition and causing metabolic 
changes, such as the increase of SCFAs able to directly act in the gut and in the brain, due to their ability to pass 
the blood brain barrier86.
Figure 8. TUNEL detection of apoptotic neurons in hippocampal area of SLAB51 treated and untreated AD 
and wt mice. Apoptotic cells are characterized by black-brownish nuclear stain, as shown in the representative 
images. (TUNEL (DeadEnd, Promega®) reaction, with Meyer’s hematoxylin nuclear counterstain. 
Bar = 200 μm.). The histogram shows the TUNEL positive cells/field. Data are representative of 5 histological 
section for each brain (n = 8 per sub-group). Data points marked with a hash are statistically significant 
compared to their respective water-treated mice (p < 0.05).
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Figure 9. Autophagic markers. Panel A: Cathepsin B and cathepsin L activity in SLAB51 treated and 
untreated wt and AD mice. Results are expressed as fluorescence units. Data points marked with an asterisk are 
statistically significant compared to their respective untreated control mice (*p < 0.05). Panels B,C,D: levels 
of the autophagy-related proteins Beclin 1, p62 and LC3-II in SLAB51 treated and untreated wt and AD mice. 
Representative immunoblots and corresponding densitometric analyses obtained from five separate blots are 
shown. Equal protein loading was verified by using an anti-GAPDH antibody. The detection was executed by an 
ECL western blotting analysis system. Data points marked with an asterisk are statistically significant compared 
to 8-week-old control mice (*p < 0.05). Data points marked with a hash are statistically significant compared 
to their respective control mice at the same time point (#p < 0.05) Original membranes strips are reported in 
Supplemental Figure 1.
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Innovatively, we show that probiotics counteracted the typical morphological alterations of AD, includ-
ing the reduction in brain weight, the decline of cortical areas, and the general brain damage and shrinkage. 
Furthermore, SLAB51 contributed to a consistent reduction in the amount of cerebral Aβ, both in the form of 
peptides and oligomers. Consequently, a decreased number and size of amyloid plaques were observed upon 
treatment. Considering a recently published work in which Lactobacillus helveticus ameliorated APP metabolism 
in cell-based assays, favored memory in mice, and reduced Aβ1–40 serum concentration in rats87, our findings 
prove a beneficial role for probiotic bacteria in AD subjects, identifying a synergistic effect obtained through the 
use of a successful formulation.
Exploring proteolytic pathways, normally impaired in AD, we evaluated the ability of the treatment to restore 
their functionality in neurons. Several papers have described dramatically impaired proteasome functionality 
in AD1, 88. For the first time, the probiotic mixture partially restored both 20S and 26S proteasomes activities. 
Enzymatic activities were confirmed through western blotting analyses investigating the levels of specific protea-
somal substrates, such as ubiquitin conjugates, p27 and p53 proteins. All these proteins accumulated with protea-
some inhibition, whereas their levels decreased upon SLAB51 treatment. In particular, as the treatment restores 
proteasome functionality, p53 levels diminished and a decrease in apoptotic levels was detected in granule cells 
from dentate gyrus of hippocampal areas, and in some pyramidal cells of the Ammon’s horn of AD treated mice. 
An increase in p53 immunoreactivity has been previously observed in sporadic AD89, 90, especially in cortical neu-
rons undergoing neurofibrillary degeneration91. The time-dependent p53 increase in untreated AD mice is also 
in agreement with a work demonstrating that p53 is upregulated approximately 2-fold in the superior temporal 
gyrus of Alzheimer’s patients compared to healthy elderly control subjects92.
Moreover, SLAB51 administration triggered autophagy, as demonstrated by the decrease of cathepsin B activ-
ity and the increase of cathepsin L activity. These lysosomal enzymes are differently involved in AD development: 
the cysteine protease cathepsin B is associated with amyloid plaques in AD brains and has been suggested to be 
responsible for the increase in Aβ production. Conversely, cathepsin L activity increases α-secretase-mediated 
non-amyloidogenic pathway. Western blotting of autophagy markers confirmed that this pathway is activated 
in treated AD mice. Therefore another pioneering piece of evidence is that the SLAB51 probiotic formulation 
restored altered autophagy in AD. Collectively, biochemical analyses on proteolysis demonstrate that SLAB51 
probiotic mixture significantly influences proteolysis, restoring impaired proteasome activities and consequently 
modulating the autophagic flux, confirming the crosstalk between the two pathways1. We believe that SLAB51’s 
positive effects on proteolysis are mediated by increased gut hormones. In fact, in a recent paper we demonstrated 
that ghrelin controls neural homeostasis through direct regulation of UPS and autophagy in AD neuronal cells93.
Furthermore, it has been demonstrated that autophagy negatively regulates Wingless-related integration site 
(Wnt) signaling, which is involved in cell migration, apoptosis and differentiation of the CNS94, and its targets, 
among them FGF9. Our results show that treatment with SLAB51 restores autophagy and modulates gut hor-
mone production in AD mice. These results suggest that microbiota composition influences Wnt signaling and 
provide an explanation of the reduced expression of FGF9 in the CNS. Increased levels of FGF9 in the hip-
pocampus of subjects with major depressive disorder have been observed. In rodent models of affective disorders, 
chronic social defeat stress increased anxiety, compromised social interaction, and decreased body weight, and 
was associated with increased hippocampal FGF9 expression95. Accordingly, FGF-9 immunoreactivity has been 
detected in human hippocampal and cortical neurons, astrocytes, and dystrophic neurites of senile plaques, in 
hippocampal sections of AD patients96. In this study an association between hippocampal FGF9 expression and 
severity of lesions related to AD in mice was observed. Therefore, reduced hippocampal expression of FGF9 in 
24-week-old AD mice treated with SLAB51, comparable to wt mice FGF9 hippocampal expression, contributes 
to the improvement of behavioral performances.
Previous studies demonstrated that modifications to the microbiota modulate the expression of several genes 
and regulate neurotransmitter and synaptic-related proteins levels, thus influencing brain development and func-
tion33, 97.
Conclusions
In this paper we provide evidence that by modulating gut microbiota several pathways are affected, consequently 
delaying AD progression. In 3xTg-AD mice, SLAB51 changed the composition of gut microbiota and its metab-
olites, positively interfering with inflammatory cytokines, gut hormones concentration and proteolysis, reducing 
Aβ load and improving cognitive function, demonstrating a role in the prevention and treatment of AD and 
supporting the idea of the gut microbiota modulation to counteract Aβ-mediated AD-type pathogenic processes.
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